Spero Therapeutics (STU:2HA) FCF Margin % : 141.24% (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Spero Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Spero Therapeutics's Free Cash Flow for the three months ended in Mar. 2024 was €5.46 Mil. Spero Therapeutics's Revenue for the three months ended in Mar. 2024 was €3.87 Mil. Therefore, Spero Therapeutics's FCF Margin % for the quarter that ended in Mar. 2024 was 141.24%.

As of today, Spero Therapeutics's current FCF Yield % is -18.49%.

The historical rank and industry rank for Spero Therapeutics's FCF Margin % or its related term are showing as below:

STU:2HA' s FCF Margin % Range Over the Past 10 Years
Min: -33344.57 Med: -1061.45 Max: -13.86
Current: -13.86

During the past 9 years, the highest FCF Margin % of Spero Therapeutics was -13.86%. The lowest was -33344.57%. And the median was -1061.45%.

STU:2HA's FCF Margin % is ranked better than
71.1% of 1045 companies
in the Biotechnology industry
Industry Median: -139.31 vs STU:2HA: -13.86

Spero Therapeutics FCF Margin % Historical Data

The historical data trend for Spero Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Spero Therapeutics FCF Margin % Chart

Spero Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

FCF Margin %

Get a 7-Day Free Trial

-1,061.41

-33,356.60

-2,095.95

-15.91

-34.11

Spero Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
FCF Margin %	Get a 7-Day Free Trial															-1,737.34	-2,356.95	68.06	-24.35	141.24

Competitive Comparison of Spero Therapeutics's FCF Margin %

For the Biotechnology subindustry, Spero Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Spero Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Spero Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Spero Therapeutics's FCF Margin % falls into.

Spero Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Spero Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2023 )	/	Revenue (A: Dec. 2023 )
	=	-30.256	/	88.706
	=	-34.11 %

Spero Therapeutics's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin	=	Free Cash Flow (Q: Mar. 2024 )	/	Revenue (Q: Mar. 2024 )
	=	5.463	/	3.868
	=	141.24 %

Spero Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Spero Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Spero Therapeutics (STU:2HA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Spero Therapeutics Inc (STU:2HA) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

SPRO:USA

Address

675 Massachusetts Avenue, 14th Floor, Cambridge, MA, USA, 02139

Website

https://www.sperotherapeutics.com

Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate, being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.

Spero Therapeutics (STU:2HA) Headlines

No Headlines